Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 08/10
279.52 AUD   +1.94%
02:34aAustralia shares end near 3-week high, buoyed by financials
RE
08/05Australia shares advance as miners, Wall Street surge
RE
08/05Australia shares end lower as corporate earnings, COVID-19 cases loom
RE
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
08/04/2020 08/05/2020 08/06/2020 08/07/2020 08/10/2020 Date
283.16 278.15 277.75 274.19 279.52 Last
1194306 896822 823340 810874 689150 Volume
+2.17% -1.77% -0.14% -1.28% +1.94% Change
Financials
Sales 2020 13 113 M 9 387 M 9 387 M
Net income 2020 3 019 M 2 162 M 2 162 M
Net Debt 2020 6 201 M 4 439 M 4 439 M
P/E ratio 2020 41,3x
Yield 2020 1,07%
Sales 2021 14 391 M 10 302 M 10 302 M
Net income 2021 3 376 M 2 417 M 2 417 M
Net Debt 2021 5 868 M 4 201 M 4 201 M
P/E ratio 2021 36,9x
Yield 2021 1,17%
Capitalization 124 B 89 334 M 89 125 M
EV / Sales 2020 9,97x
EV / Sales 2021 9,06x
Nbr of Employees 25 031
Free-Float 99,8%
More Financials
Company
CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment... 
Sector
Pharmaceuticals
Calendar
08/18 | 09:00pmEarnings Call
More about the company
Surperformance© ratings of CSL Limited
Trading Rating : Investor Rating :
More Ratings
Latest news on CSL LIMITED
02:34aAustralia shares end near 3-week high, buoyed by financials
RE
08/05Australia shares advance as miners, Wall Street surge
RE
08/05Australia shares end lower as corporate earnings, COVID-19 cases loom
RE
08/03Australia shares end flat as investors brace for business closures
RE
07/31CSL : Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
AQ
07/24Australia shares close lower on Wall Street selloff, NSW restrictions
RE
07/22Australia shares fall as record virus cases dent investor sentiment
RE
07/21Australia shares rise on stimulus, vaccine hopes
RE
07/20NEWS HIGHLIGHTS : Top Energy News of the Day
DJ
07/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/20Oil firm BJ Services files for Chapter 11 bankruptcy
RE
07/18CSL : Inaccurate Report of COVID-19 Vaccine Agreement
PU
07/16Australia shares slip; unemployment at 22-year high, virus woes hit sentiment
RE
07/15CSL : Behring's Global Role in Battling COVID-19
AQ
More news
News in other languages on CSL LIMITED
02:34aAustralia shares end near 3-week high, buoyed by financials
08/05Australia shares advance as miners, Wall Street surge
08/05Australia shares end lower as corporate earnings, COVID-19 cases loom
08/03Australia shares end flat as investors brace for business closures
07/31CSL : Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
More news
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 296,68 AUD
Last Close Price 274,19 AUD
Spread / Highest target 21,8%
Spread / Average Target 8,20%
Spread / Lowest Target -18,5%
EPS Revisions
Managers
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Brian Anthony McNamee Chairman
Paul McKenzie Chief Operating Officer
David Mark Lamont Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer, Director, Director R&D
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-0.57%89 334
BIOGEN INC.3.03%48 398
SAMSUNG BIOLOGICS CO.,LTD.77.37%42 742
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.224.31%36 982
WUXI BIOLOGICS (CAYMAN) INC.72.33%29 772
UCB46.05%23 083